Literature DB >> 17875726

Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.

Pedro Berraondo1, Clémence Nouzé, Xavier Préville, Daniel Ladant, Claude Leclerc.   

Abstract

Targeting the human papillomavirus (HPV) E7 antigen to dendritic cells with the adenylate cyclase (CyaA) of Bordetella pertussis as a vaccine vector led to potent therapeutic immune responses against TC-1 tumors in a murine model of cervical carcinoma induced by HPV. However, as the time between tumor graft and vaccination increased, the antitumor efficacy of the CyaA-E7 vaccine gradually decreased. The vaccine had no effect if the tumor diameter was >8 mm. Analyses of regulatory cells recruited during TC-1 tumor growth revealed a high number of splenic MDSCs and a large percentage of regulatory T cells, particularly in the tumor. Administration of a tritherapy including CpG complexed with a cationic lipid, low-dose cyclophosphamide, and the CyaA-E7 vaccine completely overcame tumor-associated immunosuppression and eradicated large, established tumors in almost all treated animals. This strong antitumor response was followed by a large expansion of regulatory T cells in tumor, spleen, and tumor-draining lymph nodes and of splenic neutrophils. These findings indicate that immunotherapeutic strategies that simultaneously target innate, adaptive, and regulatory components of the immune system are effective in the eradication of large tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875726     DOI: 10.1158/0008-5472.CAN-07-0321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.

Authors:  Ondrej Stanek; Irena Linhartova; Laleh Majlessi; Claude Leclerc; Peter Sebo
Journal:  Mol Biotechnol       Date:  2012-07       Impact factor: 2.695

2.  Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells.

Authors:  José Medina-Echeverz; Pedro Berraondo
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

3.  Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Authors:  Zinnia P Parra-Guillen; Pedro Berraondo; Emmanuel Grenier; Benjamin Ribba; Iñaki F Troconiz
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

4.  Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

Authors:  José I Quetglas; Juan Dubrot; Jaione Bezunartea; Miguel F Sanmamed; Sandra Hervas-Stubbs; Cristian Smerdou; Ignacio Melero
Journal:  Mol Ther       Date:  2012-06-26       Impact factor: 11.454

5.  A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.

Authors:  Zhida Liu; Hang Zhou; Wenjun Wang; Yang-Xin Fu; Mingzhao Zhu
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 6.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 7.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 8.  New trends in antitumor vaccines in melanoma.

Authors:  Marcos Vasquez; Shirley Tenesaca; Pedro Berraondo
Journal:  Ann Transl Med       Date:  2017-10

Review 9.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

10.  CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.

Authors:  Alexandre Boissonnas; Fabrice Licata; Lucie Poupel; Sébastien Jacquelin; Luc Fetler; Sophie Krumeich; Clotilde Théry; Sébastian Amigorena; Christophe Combadière
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.